imiquimod (Aldara)

10/01/2002 - "Published studies indicate that imiquimod results in complete clearance of warts in more than 50% of patients. "
01/01/2001 - "In three trials complete clearance of warts at the end of treatment plus no recurrence occurred in 37% of patients treated with imiquimod 5% cream and 4% of those treated with placebo. "
01/01/2001 - "In five trials with HIV-negative patients complete clearance of warts at the end of treatment occurred in 51% of patients treated with imiquimod 2% or 5% cream and 6% of placebo treated patients. "
08/01/1999 - "Preliminary results of a vehicle-controlled study showed that the rate of partial clearance of warts (defined as a reduction in baseline wart area of >50%) [38%] was significantly higher with imiquimod 5% cream than with vehicle cream; however, the rate of complete clearance was not significantly higher than with vehicle cream. "
03/01/1998 - "Phase III trials of imiquimod have demonstrated that patients who experience complete clearance of either new or recalcitrant warts tend to remain clear, possibly related to Th1 immune recognition and memory. "

01/01/2014 - "Although excisional surgery remains the best treatment for low-risk basal-cell carcinoma, imiquimod cream might still be a useful treatment option for small low-risk superficial or nodular basal-cell carcinoma dependent on factors such as patient preference, size and site of the lesion, and whether the patient has more than one lesion. "
01/01/2007 - "Imiquimod is a Toll-like receptor-7 agonist capable of inducing complete clearance of basal cell carcinoma (BCC) and other cutaneous malignancies. "
09/01/2004 - "Imiquimod is a modifier of the immune response that has been proven to be an effective treatment for basal cell carcinoma (BCC). "
06/01/2010 - "We conducted a prospective, multicenter, phase 3, open-label study to assess long-term sustained clearance of superficial basal cell carcinomas (sBCCs) treated with imiquimod cream 5%. "
06/01/2010 - "Sustained clearance of superficial basal cell carcinomas treated with imiquimod cream 5%: results of a prospective 5-year study."

05/01/2012 - "While randomized, controlled trials have generated information about the safety and efficacy of imiquimod 5% cream in the treatment of actinic keratosis, still very little is known about the challenges and pitfalls of this therapy in the daily clinical routine. "
01/01/2009 - "Imiquimod 5% cream applied twice weekly for 16 weeks is effective for treating actinic keratoses but may be limited by local side effects. "
08/01/2007 - "Imiquimod 3x/wk in one or two courses of treatment appears to be effective for the treatment of actinic keratoses on the head, providing long-term clinical benefits. "
08/01/2007 - "A shorter dosing regimen of imiquimod for the treatment of actinic keratosis may be effective, with long-term clinical benefits. "
07/01/2007 - "Imiquimod has been investigated as a safe and effective therapeutic option for the treatment of actinic keratosis (AK). "

04/01/2001 - "When 5% imiquimod cream is applied three times a week up to 16 weeks, approximately two thirds of women treated with imiquimod achieve complete clearance of genital warts, whereas only about one third of men clear completely. "
09/01/2000 - "The study demonstrated that 2% imiquimod in cream with mild non-objective side effects is safe, tolerable and significantly more effective than placebo in curing external genital warts in males."
07/01/1998 - "In conclusion, the data presented demonstrate that 2% imiquimod in cream with mild to moderate subjective side effects is significantly more effective than placebo in eliminating genital warts in women."
04/01/1998 - "Patient-applied 5% imiquimod cream is effective for the treatment of external genital warts and has a favorable safety profile."
04/01/2009 - "Imiquimod is a topically used immune response modifier effective in the treatment of genital warts caused by HPV. "

02/01/2013 - "Topical TLR7 agonists such as imiquimod are highly effective for the treatment of dermatological malignancies; however, their efficacy in the treatment of nondermatological tumors has been less successful. "
09/01/2004 - "Imiquimod treatment leads either to complete regression or to a significant reduction of the tumors. "
05/01/2004 - "Imiquimod, an immune response modifier with potent antiviral and antitumor properties, has been reported to be effective in the treatment of various cutaneous neoplasms. "
01/01/2007 - "Imiquimod, the lead compound of the imidazoquinoline family of nucleoside analogues, has shown good efficacy against a variety of tumors of different origin. "
06/01/2002 - "As well, we have noted a significant reduction in the development of new tumors within the imiquimod-treated area. "